Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QHEA | ISIN: US25809K1051 | Ticker-Symbol: DD2
Tradegate
14.01.25
21:04 Uhr
163,02 Euro
-1,38
-0,84 %
Branche
Internet
Aktienmarkt
NASDAQ-100
1-Jahres-Chart
DOORDASH INC Chart 1 Jahr
5-Tage-Chart
DOORDASH INC 5-Tage-Chart
RealtimeGeldBriefZeit
164,30166,7614.01.
162,40166,4214.01.
ACCESSWIRE
152 Leser
Artikel bewerten:
(1)

CBD Life Sciences Inc. in Final Stages to Sell CBD Products on DoorDash Platform

Finanznachrichten News

With DoorDash projecting over $10 billion in 2025 revenue, CBD Life Sciences Inc. is set to tap into one of the fastest-growing delivery markets in the country, potentially unlocking a multi-million dollar revenue stream and driving a projected 30-40% increase in annual revenue for CBDL.

SCOTTSDALE, ARIZONA / ACCESSWIRE / January 14, 2025 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leading innovator in the CBD industry, proudly announces that it is in the final stages of securing approval to sell its premium CBD products on DoorDash, one of the most prominent on-demand delivery platforms in the United States. This development represents a significant step forward in CBDL's ongoing strategy to broaden its market reach and deliver high-quality CBD offerings to customers with greater convenience.

DoorDash's projected multi-billion-dollar revenue for 2025 underscores the massive growth potential in on-demand services. With a footprint spanning millions of households across the nation, DoorDash provides a unique and scalable avenue for CBDL to reach an even broader audience, enhancing product accessibility and driving exponential revenue growth. The CBD industry continues to surge, and this opportunity positions CBDL as a key player in transforming how consumers access wellness products.

"Being able to sell on DoorDash opens up an entirely new market for us," said Lisa Nelson, President and CEO of CBD Life Sciences Inc. "We are excited about the prospect of making our premium CBD products available through one of the most trusted delivery platforms in the U.S. This move not only aligns with our commitment to innovation but also positions us for substantial revenue growth in 2025 and beyond."

Once approved, CBDL plans to offer a wide range of its bestselling products, including high-potency 3000MG Pain Relief Cream and CBD Gummies, with same-day delivery in select markets. The company's CBD Gummies, known for their consistency and great taste, have been a hit with customers seeking convenient, delicious ways to incorporate wellness into their daily lives. This initiative enhances CBDL's competitive edge by catering to consumer demand for fast, convenient access to wellness products.

Expanding Market Potential and Growing Investor Confidence

In addition to expanding distribution channels, this opportunity also reinforces CBDL's aggressive growth strategy aimed at increasing shareholder value. Recent industry reports indicate that the U.S. CBD market is poised to grow at a compound annual growth rate (CAGR) of 28% over the next five years, driven by increased consumer awareness and demand for natural wellness solutions. With DoorDash's extensive logistics network and CBDL's premium product line, this expansion is expected to drive significant market penetration.

CBDL's focus on innovation doesn't stop at delivery partnerships. The company is also ramping up research and development efforts to introduce new products that cater to evolving consumer needs. These efforts reflect CBDL's dedication to staying ahead of market trends and ensuring sustained growth.

"This DoorDash opportunity is a game-changer," Nelson added. "It positions us at the forefront of a rapidly evolving market and gives us a significant advantage in capturing more market share while providing a seamless buying experience for our customers. We anticipate strong revenue growth and improved brand recognition as a direct result of this initiative."

CBDL continues to explore additional partnerships and opportunities to expand its reach in both the U.S. and international markets. With a strong product portfolio, a robust distribution strategy, and a relentless focus on growth, the company remains dedicated to delivering long-term value to its investors. Additionally, the company is committed to ongoing product innovation to meet the evolving needs of health-conscious consumers.

About CBD Life Sciences Inc.

CBD Life Sciences Inc. (OTC: CBDL) is a vertically integrated company focused on the development and commercialization of high-quality, innovative CBD-based products. With a diverse product line ranging from pain relief creams to gummies, CBDL is committed to enhancing the well-being of its customers through science-backed solutions. The company's mission is to lead the CBD industry by delivering exceptional products that promote better living.

For more information about CBD Life Sciences, Inc. and its product offerings, visit www.thecbdvault.com

Doordash Website: https://www.doordash.com/

Follow our social media for the latest updates!

X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

SOURCE: CBD Life Sciences Inc.



View the original press release on accesswire.com

© 2025 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.